Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, Reagan JL, Mega A, Khurshid H, Bartley C, Lombardo A, Rossiter R, Papa A, Bakalarski P, Safran H. Mantripragada KC, et al. Among authors: reagan jl. J Oncol Pract. 2016 Apr;12(4):e396-404. doi: 10.1200/JOP.2015.008433. Epub 2016 Feb 23. J Oncol Pract. 2016. PMID: 26907448
Cellular immunotherapy for refractory hematological malignancies.
Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ. Reagan JL, et al. J Transl Med. 2013 Jun 19;11:150. doi: 10.1186/1479-5876-11-150. J Transl Med. 2013. PMID: 23782682 Free PMC article. Clinical Trial.
Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia.
Reagan JL, Fast LD, Nevola M, Mantripragada K, Mulder A, Claas FH, Rosati K, Schumacher A, Safran H, Young CT, Quesenberry MI, Winer ES, Butera JN, Quesenberry PJ. Reagan JL, et al. Blood Cancer J. 2015 Dec 4;5(12):e371. doi: 10.1038/bcj.2015.100. Blood Cancer J. 2015. PMID: 26636286 Free PMC article. Clinical Trial. No abstract available.
Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.
Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL. Ollila TA, et al. Among authors: reagan jl. Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):204-209. doi: 10.1016/j.clml.2018.01.007. Epub 2018 Jan 31. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29433979
78 results